Cosmo Technologies Ltd.
Clinical Trials
49
Trial Phases
5 Phases
Drug Approvals
1
Drug Approvals
Lumeblue (previously known as Methylthioninium chloride Cosmo)
- Authorization Status
- Authorised
- Approval Date
- Aug 19, 2020
Clinical Trials
Distribution across different clinical trial phases (32 trials with phase data)• Click on a phase to view related trials
Study to Evaluate Maximum Tolerated Dose of Oral CB-03-10 With Dose Expansion Phase, in Advanced Solid Tumors
- Conditions
- Advanced Refractory Solid TumorsSubjects Considered Likely to Respond to CB-03-10
- Interventions
- First Posted Date
- 2019-03-05
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- Cosmo Technologies Ltd
- Target Recruit Count
- 90
- Registration Number
- NCT03863145
- Locations
- 🇺🇸
University of California Irvine Health Chao Family Comprehensive Cancer Center, California City, California, United States
🇺🇸University of Colorado Cancer Center, Colorado Springs, Colorado, United States
🇺🇸Yale Cancer Center, New Haven, Connecticut, United States
Efficacy and Safety of CB-01-11 200mg Tablets in Infectious Diarrhoea
- Conditions
- Infectious Diarrhoea
- Interventions
- Drug: 1200 mg Rifamycin SV dosageDrug: 800 mg Rifamycin SV dosageDrug: 400 mg Rifamycin SV dosage
- First Posted Date
- 2018-02-27
- Last Posted Date
- 2020-02-18
- Lead Sponsor
- Cosmo Technologies Ltd
- Target Recruit Count
- 40
- Registration Number
- NCT03447821
Colon Staining Efficacy of Single Oral Doses of Methylene Blue MMX
- Conditions
- Colon Staining in Preparation for Colonoscopy
- Interventions
- Drug: Methylene Blue MMX 25 mg modified release tablets
- First Posted Date
- 2017-09-19
- Last Posted Date
- 2021-01-28
- Lead Sponsor
- Cosmo Technologies Ltd
- Target Recruit Count
- 114
- Registration Number
- NCT03287219
Rifamycin SV-MMX® 600 mg Tablets Administered Three or Two Times Daily to Patients With IBS-D
- Conditions
- Diarrhea-predominant Irritable Bowel Syndrome
- Interventions
- First Posted Date
- 2017-04-04
- Last Posted Date
- 2021-01-08
- Lead Sponsor
- Cosmo Technologies Ltd
- Target Recruit Count
- 279
- Registration Number
- NCT03099785
- Locations
- 🇧🇪
University Hospital Gasthuisberg, Department of Gastroenterology, Leuven, Herestraat 49, Belgium
🇧🇪St Lukas Ziekenhuis,, Brugge, Lucaslaan 29, Belgium
🇧🇪Clinique universitaires Saint-Luc Gastroenterologie Route 606 Avenue Hippocrate, 10, Bruxelles, Belgium
Pharmacokinetics and Safety Study of Rifamycin SV-MMX® 600 mg Tablets After Single and Multiple t.i.d. Doses in Healthy Male and Female Volunteers
- First Posted Date
- 2016-11-21
- Last Posted Date
- 2018-01-26
- Lead Sponsor
- Cosmo Technologies Ltd
- Target Recruit Count
- 18
- Registration Number
- NCT02969252
- Prev
- 1
- 2
- 3
- Next
News
Lumeblue® First Prescriptions Issued in China for Colorectal Lesion Visualization
China Medical System (CMS) announces the first prescriptions for Lumeblue® (methylthioninium chloride enteric-coated sustained-release tablets) have been issued in China.